Table 2. Characteristics of studies that took blood samples 24 h after resection.
|
Outcome result
|
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First author | Year | No. of pts | Median age (years) | Dukes/TNM stage | Blood sampling site | Time sample taken | Cellular marker used | Assay method | Positivity rate (%) | Outcome measured | CTC +ve | CTC −ve | Hazard ratio (95% CI) |
| Allen-Mersh | 2007 | 147 | 67.4 | A, B, C | P | Preop, 24 h post, 1 week post | CEA CK20 | R | 31 | DFS at 2 years | 56% | 90% | 8.6 (3.0, 24.3) |
| Bessa | 2003 | 66 | 73 | 1–3 | P | Preop, 24 h post | CEA | R | 55 | Recurrence at 36 months | 22% | 23% | 1.54 (0.4, 5.0) |
| Koch | 2006 | 90 | 66 | 2 | CV | Peri-op, 24 h post | CK20 | R | 34 | DFS at 5 years | 70% | 93% | 2.4 (1.3, 5.3) |
| Lloyd | 2006 | 146 | 74 | 1, 2 | P | Preop, intra-op, 24 h post | CEA/LAMg2/CK-20/EphB4/MAT | R | 4 | Mean survival | 42.6 m | 75.9 m | Not stated |
Abbreviations: CEA=carcinoembryonic antigen; CI=confidence interval; CK19=cytokeratin-19; CK20=cytokeratin-20; CTC=circulating tumour cell; CV=central venous; DFS=disease free survival; GCC=guanylyl cyclase-C; hTERT=human telomerase reverse transciptase; MA=membrane array; MAT=matrilysin; LAMg2=laminin-5g2; mes=mesenteric; OS=overall survival; P=peripheral; Po=portal; R=reverse-transcriptase-PCR.